iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401

MT Newswires09-17

iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.

Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.

Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.

The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.

iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468801165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-17 10:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468801165","market":"sg","top_or_hot":-1,"title":"iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401","media":"MT Newswires","content":"<html><body><p> iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.</p><p>Following the end of its licensing agreement with Seelos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.</p><p>Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.</p><p>The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.</p><p>iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>iX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\niX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for iXB 401\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-17 10:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"42C.SI","symbol_name":"IX生物制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468801165","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468801165","pubTimestamp":1726540898,"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"iX Biopharma  has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome  and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"42C.SI":"IX生物制药","BK6079":"制药","BK6506":"制药与医学研究概念"},"translate_title":"iX Biopharma推进Wafermine外包许可，开始iXB 401的临床前试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"42C.SI":0.9},"content_text":"iX Biopharma (SGX:42C) has updated its progress on Wafermine and iXB 401, according to a Monday filing on the Singapore Exchange.Following the end of its licensing agreement with Seelos Therapeutics, iX Biopharma has engaged Kybora, a global life sciences advisory firm, to assist in out-licensing Wafermine, a sublingual ketamine wafer.Kybora will help the company explore licensing opportunities in key markets for Complex Regional Pain Syndrome (CRPS) and depressive disorders. Wafermine's Orphan Drug Designation from the US FDA emphasizes its potential as a non-opioid treatment option.The company has also begun preclinical testing for iXB 401, a sublingual semaglutide wafer for Type 2 diabetes and obesity.iX Biopharma has developed various formulations and appointed a clinical research organization to conduct studies in diabetic mice. iXB 401 aims to improve patient compliance and address supply and environmental challenges associated with current GLP-1 treatments.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468801165"}